Edgewise Therapeutics has shared positive results in its Sevasemten program for Becker and Duchenne muscular dystrophies.
Highlights include:
● New open-label data in Becker from the open-label MESA trial demonstrated sustained disease stabilization up to three years in participants, reinforcing prior clinical findings from the ARCH and CANYON trials.
● Pivotal trial, GRAND CANYON, is ongoing and a recently completed FDA Type C meeting provides a clear path to potential registration as the first evertherapy for Becker.
● Encouraging Phase 2 observations in Duchenne from the LYNX and FOX trials define the dose and inform design for a Phase 3 study.
Please read the full press release for more information.
We remain steadfast in our commitment to supporting individuals and families living with Duchenne. If you have any questions or concerns regarding this news, please do reach out to us at info@actionduchenne.org
Want to know more about the important topics in Duchenne? With subjects ranging from bone health and puberty to positive engagement through technology, our 2025 free webinars aim to address the topics raised by the community, and delivered by leading experts. Visit our webinar home page and find out more!
